AmpliPhi BioSciences Corporation (APHB)

0.32
AMEX
Prev Close 0.32
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.15 / 1.37
Exchange AMEX
Shares Outstanding 32.77B
Market Cap 10.41M
Div & Yield N.A. (N.A)
Lifshitz & Miller LLP Announces Investigation Of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., And Uniti Financial Corporation

Lifshitz & Miller LLP Announces Investigation Of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., And Uniti Financial Corporation

NEW YORK, April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AmpliPhi Biosciences Corporation - APHB

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AmpliPhi Biosciences Corporation - APHB

NEW YORK, March 27, 2019 /PRNewswire/ --  Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of...

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the fourth quarter and full...

AmpliPhi Biosciences And C3J Therapeutics Agree To Merge

AmpliPhi Biosciences And C3J Therapeutics Agree To Merge

AmpliPhi Biosciences Corporation ("AmpliPhi") (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and C3J Therapeutics, Inc.

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process And Scale Up For AB-SA01 Clinical Development

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process And Scale Up For AB-SA01 Clinical Development

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today...

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the third quarter ended...

AmpliPhi Biosciences Announces Closing Of Public Offering

AmpliPhi Biosciences Announces Closing Of Public Offering

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today...

AmpliPhi Biosciences Announces Pricing Of $6.6 Million Underwritten Public Offering

AmpliPhi Biosciences Announces Pricing Of $6.6 Million Underwritten Public Offering

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today...

AmpliPhi Biosciences Announces Presentation Of Positive Clinical Data From Its Expanded Access Program For Serious S. Aureus Infections At IDWeek 2018 Conference

AmpliPhi Biosciences Announces Presentation Of Positive Clinical Data From Its Expanded Access Program For Serious S. Aureus Infections At IDWeek 2018 Conference

AmpliPhi Biosciences Corporation (NYSE American:APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of clinical case series data from...

AmpliPhi Biosciences To Present Clinical Case Series Data At IDWeek 2018

AmpliPhi Biosciences To Present Clinical Case Series Data At IDWeek 2018

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that clinical case series data from the company's...

AmpliPhi Biosciences Announces Positive FDA Feedback For Its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

AmpliPhi Biosciences Announces Positive FDA Feedback For Its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback,...

AmpliPhi Biosciences Announces Positive FDA Feedback For Its Clinical Stage Bacteriophage Product Candidate AB-SA01

AmpliPhi Biosciences Announces Positive FDA Feedback For Its Clinical Stage Bacteriophage Product Candidate AB-SA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company had a Type B Pre-IND meeting with...

AmpliPhi Biosciences Announces Updated Positive Clinical Results For Its Expanded Access Program

AmpliPhi Biosciences Announces Updated Positive Clinical Results For Its Expanded Access Program

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing...

AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the second quarter ended...

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Studies At American Society Of Microbiology Annual Meeting

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Studies At American Society Of Microbiology Annual Meeting

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four...

AmpliPhi Biosciences Announces Presentation Of AB-PA01 Bacteriophage Therapy Case Study At 41st European Cystic Fibrosis Conference

AmpliPhi Biosciences Announces Presentation Of AB-PA01 Bacteriophage Therapy Case Study At 41st European Cystic Fibrosis Conference

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a poster presentation of a successful case study...

AmpliPhi Biosciences To Present At 5th World Congress On Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

AmpliPhi Biosciences To Present At 5th World Congress On Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced its participation in the 5 th World Congress on...

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the first quarter ended...

AmpliPhi Biosciences To Hold 2018 First Quarter And Business Update Conference Call On May 15

AmpliPhi Biosciences To Hold 2018 First Quarter And Business Update Conference Call On May 15

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business...

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services To Advance Development Of Its Targeted Therapeutic Candidate For The Treatment Of Resistant Staphylococcus Aureus

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services To Advance Development Of Its Targeted Therapeutic Candidate For The Treatment Of Resistant Staphylococcus Aureus

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development...

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Study At ISHLT Annual Meeting

AmpliPhi Biosciences Announces Presentation Of Bacteriophage Therapy Case Study At ISHLT Annual Meeting

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation...

AmpliPhi Biosciences Announces Closing Of Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Announces Closing Of Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the closing of its previously...

AmpliPhi Biosciences Announces Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Announces Registered Direct Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into...

AmpliPhi To Collaborate With Western Sydney Local Health District And Westmead Institute For Medical Research On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi To Collaborate With Western Sydney Local Health District And Westmead Institute For Medical Research On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a collaboration...

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results...

AmpliPhi To Collaborate With The U.S. Department Of Veterans Affairs On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi To Collaborate With The U.S. Department Of Veterans Affairs On Expanded Access For Investigational Bacteriophage Therapeutics AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a Cooperative...

AmpliPhi Biosciences Announces Presentation Of Preclinical Data Demonstrating That AB-PA01 Reduces Biofilm In Pseudomonas Aeruginosa In Vivo Model

AmpliPhi Biosciences Announces Presentation Of Preclinical Data Demonstrating That AB-PA01 Reduces Biofilm In Pseudomonas Aeruginosa In Vivo Model

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation...

AmpliPhi Biosciences Announces Pricing Of $4.0 Million Public Offering Of Common Stock

AmpliPhi Biosciences Announces Pricing Of $4.0 Million Public Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a...

AmpliPhi Biosciences Announces Proposed Public Offering Of Common Stock

AmpliPhi Biosciences Announces Proposed Public Offering Of Common Stock

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends...

AmpliPhi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program Utilizing AB-SA01 And AB-PA01

AmpliPhi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program Utilizing AB-SA01 And AB-PA01

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced topline results...